CareDx, Inc. Adopts Amendments to Outside Director Compensation PolicyOn January 6, 2025, CareDx, Inc. (NASDAQ: CDNA) made updates to its outside director compensation policy. The Compensation and Human Capital Committee of the Board of Directors of

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read CareDx’s 8K filing here.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.